Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Teclistamab and other B-cell maturation antigen (BCMA)–targeting bispecific antibodies
(BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) …

In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA
vaccination on COVID-19 disease incidence and outcomes in patients with hematologic …

Patients affected by lymphoid malignancies (LM) are frequently immune‐compromised,
suffering increased mortality from COVID‐19. This prospective study evaluated serological …

In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …

Background As vaccine roll-out continues across the globe as part of the efforts to protect
humanity against SARS-CoV-2, concerns are increasingly shifting to the duration of vaccine …

The objectives of this study were to assess the immunogenicity and safety of COVID-19
vaccines in patients with hematologic malignancies. A systematic review and meta-analysis …

Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …

Patients with multiple myeloma frequently present with substantial immune impairment and
an increased risk for infections and infection-related mortality. The risk for infection with …